01—Abstract
Summary
Summary of the 8-K filed May 18, 2026. Cited figures are marked; the original filing is the authoritative source.
CVS Health Corporation (CVS) filed an 8-K report on May 18, 2026, detailing the outcomes of its 2026 Annual Meeting of Stockholders held on May 14, 2026.
The primary focus of this filing is the shareholder approval of the new 2026 Incentive Compensation Plan (ICP), which will replace the existing 2017 plan for awards granted after May 14, 2026. This plan was overwhelmingly approved by stockholders, signaling confidence in the company's executive compensation strategy moving forward. In addition to the approval of the 2026 ICP, the filing confirms the re-election of all 13 nominated directors for one-year terms.
Stockholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2026 and approved, on an advisory basis, the compensation of the company's named executive officers. A single stockholder proposal regarding the reduction of the threshold for stockholder action by written consent was not approved.
02—Key points
Key Highlights
- Stockholder approval of the 2026 Incentive Compensation Plan (ICP), replacing the 2017 ICP for future awards.
- Re-election of all 13 nominees to the Board of Directors for one-year terms.
- Ratification of Ernst & Young LLP as the independent registered public accounting firm for 2026.
- Advisory approval of the compensation for named executive officers.
- A stockholder proposal to reduce the threshold for action by written consent was not approved.
- A quorum was established with 1,142,802,406 shares of common stock represented.
- The 2026 ICP received strong support, with over 1 billion shares voting in favor.
03—Questions
Frequently Asked Questions
What is the main purpose of this 8-K filing?
The main purpose of this 8-K filing is to report the results of CVS Health Corporation's 2026 Annual Meeting of Stockholders, specifically highlighting the approval of the 2026 Incentive Compensation Plan and the outcomes of other voting matters presented to shareholders.
What is the 2026 Incentive Compensation Plan?
The 2026 Incentive Compensation Plan (ICP) is a new equity and incentive award plan approved by CVS Health stockholders. It replaces the company's previous 2017 Incentive Compensation Plan and will govern awards granted to eligible participants after May 14, 2026. Specific details of the plan were previously outlined in the company's Proxy Statement.
Were there any significant 'no' votes on important proposals?
The most notable 'no' vote was on the stockholder proposal to reduce the threshold for the company's stockholder right to act by written consent, which was not approved. All other major proposals, including the election of directors, ratification of auditors, executive compensation, and the 2026 ICP, received overwhelming shareholder approval.
Who is CVS Health's independent auditor for 2026?
Ernst & Young LLP has been ratified by CVS Health's stockholders as the company's independent registered public accounting firm for the fiscal year 2026.
04—Continue